Latest june eyecare news:

Aurion Biotech have announced their CEO, Greg Kunst. Aurion is developing a platform of advanced therapies to treat ocular diseases, starting with a cell therapy to treat corneal endothelial disease.

Biogen have announced that their BIIB111 treatment (timrepigene emparvovec) for choroideremia has not met its 1-year target in correcting visual acuity. They are reviewing the data for their treatment before deciding on the next steps for their gene therapy program.

EyeYon Medical have received CE Mark for its EndoArt after clinical trails proved its safety and efficacy for treating chronic corneal edema. EndoArt the first synthetic implant that replaces the human endothelium that the human body can’t regenerate. “We are proud to receive CE mark for our unique EndoArt implant, which is set to transform the way patients with chronic corneal edema are treated,” Nahum Ferera, co-Founder and CEO of EyeYon Medical.

Implandata Ophthalmic Products announced that their EYEMATE-SC biosensor has received a CE Mark. This works alongside their EYEMATE system which allows glaucoma to be monitored and managed digitally and remotely. “Obtaining CE mark for our less invasive EYEMATE-SC sensor as part of our validated EYEMATE system is another important step forward for the company to transform glaucoma care,” Max G. Ostermeier, CEO and Founder of Implandata.

LENZ Therapeutics is developing a proprietary eye drop formulation of aceclidine. This month they debuted a $47 million Series A financing to move these eyedrops forward toward an NDA submission for the treatment of presbyopia.

Ref: https://eyewire.news/articles/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/ https://eyewire.news/articles/lenz-therapeutics-debuts-with-47-million-series-a-financing/ https://eyewire.news/articles/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/ https://eyewire.news/articles/greg-kunst-appointed-ceo-of-aurion-biotech/